Insmed (INSM) Stock Highlights

55.05 | -3.39%

2024-06-02 23:47:55

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The companys first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The companys earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

Statistics

Range Today

53.69 57.61

Volume Today 7.19M

Range 1 Year

18.63 58.82

Volume 1 Year 435.07M

Range 3 Year

16.04 58.82

Volume 3 Year 971.44M

Range 10 Year

9.02 58.82

Volume 10 Year 2.35B

Highlights

Market Capitalization 8.18B (mid)

Floating Shares 147.03M

Current Price 55.05

Price To Earnings -10.9

Price To Revenue 29.29

Earnings Per Share -5.23

Payout Ratio 0%

Performance

Latest -3.39%

1 Month +119.24%

3 Months +95.07%

6 Months +120.55%

1 Year +193.29%

3 Years +120.2%

5 Years +122.42%

10 Years +319.27%

Benchmarks

Market Capitalization

39 / 368

Gross Profits

33 / 278

Total Revenue

43 / 300

Total Rank

161 / 368

Free Cashflow

344 / 352

Performance 5 years

52 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.